フォテムスチン

Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, re

Chemical data

Formula: C9H19ClN3O5P
Molecular weight: 315.69 g/mol
IUPAC name: 1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea
SMILES: CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
InChIKey: YAKWPXVTIGTRJH-UHFFFAOYSA-N
XLogP: 0.9
Polar surface area: 97.3 Å²
H-bond donors: 1
H-bond acceptors: 6
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Phase 3
Molecule type: Small molecule
Indications: neoplasm, glioblastoma multiforme, cutaneous melanoma, melanoma

via ChEMBL · EBI

Research

415 papers

Fotemustine for the treatment of melanoma.Expert opinion on pharmacotherapy · 2011
Fotemustine in the treatment of brain primary tumors and metastases.Cancer investigation · 1994
Fotemustine in recurrent high‑grade glioma: MRI neuro‑radiological findings.Oncology letters · 2024
An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.BioMed research international · 2014
Focus on Fotemustine.Journal of experimental & clinical cancer research : CR · 2006

via PubMed

Wikidata facts

Subclass of: chemical compound
Mass: 315.075
Has use: medication

Show 4 more facts

chemical formula: C₉H₁₉ClN₃O₅P
canonical SMILES: CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
subject has role: antineoplastic
Commons category: Fotemustine

Sources (2)

via Wikidata · CC0

Article · 日本語

フォテムスチン(Fotemustine)は、転移性の悪性黒色腫の治療に用いられているニトロソウレア系のアルキル化剤である。ある研究では、フォテムスチンはダカルバジンと比べて、播種性の皮膚悪性黒色腫の治療におけるは高まるが、生存率は改善しないとの結果が出ている。生存期間の中央値は、フォテムスチンで7.3ヶ月、ダカルバジンで5.6ヶ月である。また、フォテムスチンは毒性も持つ。主な毒性は、好中球減少症（ダカルバジンの5%に対して51%）と血小板減少症（ダカルバジンの6%に対して43%）である。

Abstract from DBpedia / Wikipedia · CC BY-SA

Available in 11 languages

via Wikidata sitelinks · CC0